Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Glenmark's cancer drug delivers high response in phase-1 trial, shows 74% response: Our Bureau, Mumbai Tuesday, June 3, 2025, 16:45 Hrs [IST] Ichnos Glenmark Innovation (IGI), a g ...

The early-stage trial results signal promise for ISB 2001, a first-in-class trispecific antibody being developed for patients ...

ISB 2001 was designed to simultaneously target multiple myeloma by binding to the tumor- associated antigens BCMA and CD38, even when expressed at low levels, while engaging T cells to ...

While imports can swing with seasonal shifts, President Trump’s ratcheting up of U.S. tariffs on China has begun to cascade through supply chains, government data shows. China’s share of all U ...

Building on these data, the preclinical PK model tracked the plasma levels of the CD38-SADA protein. Importantly, the model's estimated linear clearance of low molecular weight CD38-SADA monomers was ...

Building on these data, the preclinical PK model tracked the plasma levels of the CD38-SADA protein. Importantly, the model’s estimated linear clearance of low molecular weight CD38-SADA ...

Building on these data, the preclinical PK model tracked the plasma levels of the CD38-SADA protein. Importantly, the model’s estimated linear clearance of low molecular weight CD38-SADA ...

Cytopenias: low levels of red blood cells ... Darzalex, according to the National Cancer Institute, binds to the protein CD38 found on some types of immune cells and cancer cells, including myeloma ...

MSCs were shown to constitutively express low levels of c-kit which could be en-hanced by SCF. G-CSF and SCF had an obvious facilitative effect on the proliferation of MSCs in a dose-dependent fashion ...